Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

BMC Cancer

Shen-Shong Chang²  Hsiao-Yun Hu¹ 

[1] Department of Education and Research, Taipei City Hospital, Taipei, Taiwan

[2] School of Medicine, National Yang-Ming University, Taipei, Taiwan

关键词: Diabetes mellitus;    Case–control;    Gastric cancer;    Thiazolidinediones;    Peroxisome proliferator-activated receptors;   

Others  :  1079570
DOI  :  10.1186/1471-2407-13-420

 received in 2012-12-21, accepted in 2013-09-10,  发布年份 2013

【 摘 要 】

Background

It has been shown that peroxisome proliferator-activated receptors (PPAR) have physiological and pharmacological ligands. The objective is to assess the association between thiazolidinediones (TZDs) and the occurrence of gastric cancer.

Methods

We conducted a population-based nested case–control study. Data were retrospectively collected from the National Health Insurance Research Database (NHIRD). The cases consisted of all diabetes mellitus (DM) patients aged 30 to 99 years, and who had a first time diagnosis of gastric cancer in the study cohort. The controls were matched to cases by age, sex, and index date. The adjusted odds ratio (OR) and 95% confidence interval (CI) were estimated by using multiple logistic regression.

Results

Records from 357 gastric cancer and 1,428 selected matched controls were included in the analyses of gastric cancer risk. A total of 7% or 9.5% of the cases and 10.8% or 14.8% of the controls had used any quantity of at least 2 prescriptions for pioglitazone or rosiglitazone, respectively. After adjusting for possible confounders, pioglitazone (OR = 0.93, P > 0.05) and rosiglitazone (OR = 1.21, P > 0.05), had no significant association of decreasing gastric cancer. After adjusting for possible confounders, pioglitazone (OR = 0.70, P > 0.05) or rosiglitazone (OR = 0.79, P > 0.05), had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 260 defined daily doses (DDDs), respectively. Moreover, adjusting for possible confounders pioglitazone (OR = 0.68, P > 0.05) or rosiglitazone (OR = 0.74, P > 0.05) had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 1 year, respectively.

Conclusions

Our results did not show evidence to support that TZD derivatives in DM patients reduces gastric cancer occurrence.

【 授权许可】

   
2013 Chang and Hu; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
• [2]Nicolucci A: Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010, 47:87-95.
• [3]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
• [4]Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008, 9:1039-1047.
• [5]Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ, American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee: American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006, 56:254-281.
• [6]Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009, 10:1033-1034.
• [7]Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
• [8]Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
• [9]Theocharis S, Margeli A, Vielh P, Kouraklis G: Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004, 30:545-554.
• [10]Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000, 405:421-424.
• [11]Panigrahy D, Shen LQ, Kieran MW, Kaipainen A: Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 2003, 12:1925-1937.
• [12]Martelli ML, Iuliano R, Le Pera I, Sama’ I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A: Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002, 87:4728-4735.
• [13]Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998, 95:8806-8811.
• [14]Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:2170-2177.
• [15]Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N, Kinoshita Y: Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001, 84:1640-1647.
• [16]Heaney AP, Fernando M, Melmed S: PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003, 111:1381-1388.
• [17]Giaginis C, Theocharis S, Tsantili-Kakoulidou A: A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives. Expert Opin Investig Drugs 2007, 16:413-417.
• [18]Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, Kadowaki T, Kubota N, Terauchi Y, Ishii G, Ochiai A, Esumi H, Kaminishi M: Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005, 65:4769-4774.
• [19]Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999, 455:135-139.
• [20]Konturek PC, Kania J, Kukharsky V, Raithel M, Ocker M, Rembiasz K, Hahn EG, Konturek SJ: Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J Pharmacol Sci 2004, 96:134-143.
• [21]Jick H, Garcia Rodriguez LA, Perez-Gutthann S: Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998, 352:1767-1770.
• [22]Essebag V, Platt RW, Abrahamowicz M, Pilote L: Comparison of nested case–control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005, 5:5. BioMed Central Full Text
• [23]WHO Collaborating Center for Drugs Statistics Methodology: ATC Index with DDDs 2003. Oslo: WHO; 2003.
• [24]Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA: Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012, 55:1462-1472.
• [25]Hsiao FY, Tsai YW, Wen YW, Kuo KN, Tsai CR, Huang WF: Effect of helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event. Pharmacotherapy 2011, 31:239-247.
• [26]Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF: Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 2007, 7:175. BioMed Central Full Text
• [27]Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ: Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004, 53:331-338.
• [28]Cheon CW, Kim DH, Cho YH, Kim JH: Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol 2009, 15:310-320.
• [29]Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
• [30]Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vazquez-Carrera M: Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008, 57:2149-2157.
• [31]Slomiany BL, Slomiany A: Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation. IUBMB Life 2002, 53:303-308.
• [32]Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, Peek RM Jr: Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001, 276:31059-31066.
• [33]Talley NJ, Fock KM, Moayyedi P: Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008, 103:510-514.
• [34]Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009, 137:1641-1648.
• [35]Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY: Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010, 19:745-751.
• [36]Ma XM, Yu H, Huai N: Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. World J Gastroenterol 2009, 15:3874-3883.